Quidditas Therapeutics, a Liège, Belgium-based biotechnology company which specializes in genome editing, raised €2.62M in funding.
The round was led by iXLife Capital with participation from Key Ventures, family companies and business angels. The investment was complemented by a €1.72M grant from the Ministry of Research in Wallonia via the Win4Company program, a public initiative supporting companies in the Walloon region of Belgium.
The company intends to use the funds to further enhance its R&D efforts and the development of its recombination-based genome editing technology.
Founded in December 2022 by François Cherbonneau, PhD, M.Eng, and Aurore Prunevieille, PhD, M.Eng, Quidditas is a biotechnology company developing a precise and adaptable genome editing platform with multiple applications across gene therapy, protein bioproduction and regenerative medicine.
Its approach could be used to address some of the most complex and rare diseases through gene therapy, while also opening new opportunities in bioproduction, stem cell research and other biomedical fields.
FinSMEs
12/05/2025